Inhibrx reports Q3 net loss $35.3M; ozekibart meets primary endpoint in chondrosarcoma

Inhibrx Biosciences, Inc.

2025-Q3 EPS reported -$6.93 vs consensus -$1.75 ▼ miss (-295.5%)

Net loss of $35.3M ($2.28 per share) vs $43.9M ($2.84) in Q3 2024; R&D expense down to $28.5M.
Cash and equivalents $153.1M at Sept 30, 2025, down from $186.6M at June 30, 2025.
Ozekibart (INBRX-109) met primary endpoint in registrational chondrosarcoma trial, showing statistically significant PFS improvement.
Plan to submit BLA to FDA in Q2 2026; expansion cohorts in colorectal cancer and Ewing sarcoma show high response rates.
$100M debt outstanding; interest expense of $3.2M in Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.